成人急性淋巴细胞白血病管理的新方法
综述探讨成人急性淋巴细胞白血病治疗进展:传统方案总生存约40%,儿童型方案使年轻成人提高至约60%,酪氨酸激酶抑制剂和微小残留病检测进一步改善结局。复发和毒性仍是主要问题,单克隆抗体、免疫调节剂和嵌合抗原受体T细胞等新药有望进一步改善疗效。
要点
- 传统成人ALL方案总生存约40%,儿童型方案使年轻成人提高至约60%。
- 酪氨酸激酶抑制剂和微小残留病指导的风险分层改善了费城染色体阳性患者结局。
- 单克隆抗体、免疫调节剂和嵌合抗原受体T细胞是当前最有前景的新疗法。
核心结论
- 新治疗工具和方案在成人急性淋巴细胞白血病不同亚组中作用日益增强,基于精准医学理念已可为患者确定最佳个体化方案。
研究设计与样本
- 综述,检索并分析支持新治疗工具和方案在成人急性淋巴细胞白血病不同疾病亚组中应用的证据,涵盖一线及复发或难治性疾病。
主要发现
- 传统成人方案总生存约40%,儿童型方案使年轻成人总生存提高至约60%。
- 费城染色体阳性患者加用酪氨酸激酶抑制剂及微小残留病指导的风险分层和缓解后策略进一步改善结局。
- 复发疾病和治疗毒性仍是当前最关键的未满足问题,尤其在老年患者中。
- 对疾病生物学(特别是费城染色体样特征及其他高危亚组)的认识取得进展。
- 单克隆抗体、免疫调节剂和嵌合抗原受体T细胞是最有前景的新药,靶向白血病细胞生长和增殖关键分子通路的新药前景相对较小。
临床怎么用
- 基于精准医学的新理念,现已可为成人急性淋巴细胞白血病患者确定最佳个体化治疗策略。
局限性
- 复发疾病和治疗毒性仍是当前最关键的未满足问题,尤其在老年患者中。
- 靶向白血病细胞生长和增殖关键分子通路的几种新药前景相对较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Traditional treatment regimens for adult acute lymphoblastic leukemia, including allogeneic hematopoietic cell transplantation, result in an overall survival of approximately 40%, a figure hardly comparable with the extraordinary 80% to 90% cure rate currently reported in children. When translated to the adult setting, modern pediatric-type regimens improve the survival to approximately 60% in young adults. The addition of tyrosine kinase inhibitors for patients with Philadelphia chromosome-positive disease and the measurement of minimal residual disease to guide risk stratification and postremission approaches has led to additional improvements in outcomes. Relapsed disease and treatment toxicity-sparing no patient but representing a major concern especially in the elderly-are the most critical current issues awaiting further therapeutic advancement. Recently, there has been considerable progress in understanding the disease biology, specifically the Philadelphia-like signature, as well as other high-risk subgroups. In addition, there are several new agents that will undoubtedly contribute to additional improvement in the current outcomes. The most promising agents are monoclonal antibodies, immunomodulators, and chimeric antigen receptor T cells, and, to a lesser extent, several new drugs targeting key molecular pathways involved in leukemic cell growth and proliferation. This review examines the evidence supporting the increasing role of the new therapeutic tools and treatment options in different disease subgroups, including frontline and relapsed or refractory disease. It is now possible to define the best individual approach on the basis of the emerging concepts of precision medicine.
引用
- Bassan R, Bourquin JP, DeAngelo DJ, et al. New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 2018. PMID: 30240326. doi:10.1200/JCO.2017.77.3648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。